EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Clofarabine Preconditioning followed by Allogeneic Transplant Using TBI and Post-Transplant Cyclophosphamide for Relapsed Refractory Leukemia

Seema Naik iD, Kevin Rakszawski iD, Hong Zheng, David Claxton iD, Kentaro Minagawa, Shin Mineishi

International Journal of Molecular Sciences · 12.01.2024 · 25 (2) · 957

DOI: 10.3390/ijms25020957 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.01.2024. Verfasst von Seema Naik und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Penn State Cancer Institute, 500 University Dr. Hershey, Hershey, PA 17033, USA. Hauptthemen laut MEDLINE: Graft vs Host Disease, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Arlene Witmer Memorial Fund for Bone Marrow Cancer Research, The John and Denise Gilliland Fund for the Cancer Genetics Program, G. R. Sponaugle Employee Cancer Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia patients with induction failure or relapsed refractory disease have minimal chance of achieving remission with subsequent treatments. Several trials have shown the feasibility of clofarabine-based conditioning in allogeneic stem cell transplants (allo-HSCT) for non-remission AML patients. Pre-transplant conditioning with clofarabine followed by reduced-intensity allo-HSCT has also demonstrated a potential benefit in those patients with human leukocyte antigen (HLA)-identical donors, but it is not commonly used in haploidentical and mismatched transplants. In this case report, we describe our experience of seven cases of non-remission AML who received clofarabine preconditioning followed by an allo-HSCT with PTCy. The 2-year overall survival and disease-free survival was 83.3% (95% confidence interval (CI): 27.3–97.9%) and 85.7% (95% CI: 33.4–97.9%). Median days of neutrophil and platelet recovery were 16 (range of 13–23) and 28 (range of 17–75), respectively. The cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) at day 100 and chronic GVHD at 1-year showed 28.6% (95% CI: 8–74.2%) and 28.6% (95% CI: 3–63.9%), respectively. The two-year relapse rate was 14.3% (95% CI: 2.14–66.6%). One-year GVHD-free relapse-free survival (GFRS) at 1-year was 71.4% (95% CI: 25.8–92%). Our patients showed successful outcomes with clofarabine preconditioning to reduce the leukemic burden at the pre-transplant period followed by PTCy to reduce GVHD resulting in lower relapsed rate and better GFRS in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseLeukemia, Myeloid, AcuteHumansClofarabineCyclophosphamideAllografts

Stichwörter der Autor:innen

AML: acute myeloid leukemiaAllo-HSCT: allogeneic transplantClo: clofarabinePTCy: post-transplant cyclophosphamide

Substanzen

ClofarabineCyclophosphamide

Autor:innen und Institutionen

  • Department of Medicine, Penn State Cancer Institute, 500 University Dr. Hershey, Hershey, PA 17033, USA.

ORCID-Profile: Seema Naik, Kevin Rakszawski, David Claxton

Förderung

  • The Arlene Witmer Memorial Fund for Bone Marrow Cancer Research
  • The John and Denise Gilliland Fund for the Cancer Genetics Program
  • G. R. Sponaugle Employee Cancer Research Fund
  • Richard E. and Stephanie A. Ziegler Charitable Foundation Endowment in Hematology

Zitieren

APA

Naik, S., Rakszawski, K., Zheng, H., Claxton, D., Minagawa, K., & Mineishi, S. (2024). Clofarabine Preconditioning followed by Allogeneic Transplant Using TBI and Post-Transplant Cyclophosphamide for Relapsed Refractory Leukemia. International Journal of Molecular Sciences, 25(2), 957. https://doi.org/10.3390/ijms25020957

Vancouver

Naik S, Rakszawski K, Zheng H, Claxton D, Minagawa K, Mineishi S. Clofarabine Preconditioning followed by Allogeneic Transplant Using TBI and Post-Transplant Cyclophosphamide for Relapsed Refractory Leukemia. International Journal of Molecular Sciences. 2024;25(2):957. doi:10.3390/ijms25020957

BibTeX
@article{Naik2024,
  author = {Naik, Seema and Rakszawski, Kevin and Zheng, Hong and Claxton, David and Minagawa, Kentaro and Mineishi, Shin},
  title = {Clofarabine Preconditioning followed by Allogeneic Transplant Using TBI and Post-Transplant Cyclophosphamide for Relapsed Refractory Leukemia},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {2},
  pages = {957},
  doi = {10.3390/ijms25020957}
}
Kostenlos starten →